President Donald Trump on Thursday announced a White House deal with drugmakers Eli Lilly and Novo Nordisk to lower prices and expand coverage for their GLP-1 medications Zepbound and Wegovy, widely used for weight loss.

"The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions," the White House said in a statement.

WATCH | Trump announcement on lowering GLP-1 drug costs White House announcement on the popular weight-loss drug GLP-1

The agreement — part of Trump's Make America Healthy Again initiative — is aimed at reducing drug prices for millions of Americans. The medicatio

See Full Page